1. Scrip
  2. >>Leadership

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

 
• By Mandy Jackson

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Ionis CEO Brett Monia
Brett Monia was a founding scientist at Ionis • Source: Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. has monetized its expertise in antisense drug discovery by linking up with bigger biopharmaceutical companies to lead late-stage development and commercialization. But going forward, new CEO Brett Monia said, the company will be more selective about entering into new collaborations and prioritize Ionis-owned drug candidates.

Scrip spoke with Monia about Ionis’s future in an interview at the J.P. Morgan Healthcare Conference earlier this month in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Executives On The Move: New CEOs At Sun Pharma And TME Pharma

Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 
• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

More from Scrip

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.